Minneapolis, MNNCT07591649Now EnrollingIRB Ready

Relapsed Adult AML Clinical Trial in Minneapolis, MN

Access cutting-edge relapsed adult aml treatment through this clinical trial at a research site in Minneapolis. Study-provided care at no cost to qualified participants.

Sponsored by Masonic Cancer Center, University of Minnesota

Quick Self-Assessment

See if you qualify for this Minneapolis location

Preparing your pre-screening questions…

Expert Care in Minneapolis

Access relapsed adult aml specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related relapsed adult aml treatment provided free

Apply for This Minneapolis Location

Check if you qualify for this relapsed adult aml clinical trial in Minneapolis, MN

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Minneapolis

    Convenient for MN residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Minneapolis site if eligible
  4. 4Begin participation

About This Relapsed Adult AML Study in Minneapolis

This is a multi-institutional Phase I/II study of an allogeneic KIR-HLA mismatched NK cell infusion (AdaptNK) and a short course of subcutaneous interleukin-2 (IL-2) administered after lymphodepleting chemotherapy \[cyclophosphamide (CY)/fludarabine (FLU)\] in patients with relapsed or refractory acute myelogenous leukemia (AML). AdaptNK is a natural killer (NK) cell product that is enriched for NK cells with an "adaptive", or human cytomegalovirus (CMV)-induced, phenotype.

Sponsor: Masonic Cancer Center, University of Minnesota

Who Can Participate

Inclusion Criteria

18-74 years with Karnofsky score ≥ 70%
75 years and older: KPS ≥ 70%, HCT-CI \< 5 (excluding history of solid tumor), AND not frail by Fried frailty criteria (see Appendix III)
HLA type C1/C1 or C2/C2 Note: For easy determination, the definition of HLA-C ligand group assigments is included below: HLA-C1 group alleles are defined as HLA-C01, C03, C07, C08, C12, C14, C16 HLA-C2 group alleles are defined as HLA-C02, C04, C05, C06, C15, C17, C18
adequate liver, renal, pulmonary and cardiac function
ability to be off glucocorticoids and other immunosuppressive medications indicated for acute or chronic GVHD for at least 28 days prior to the AdaptNK cell infusion
There must be sufficient time between the most recent therapy and the screening bone marrow as delineated below:
anti-leukemic systemic cytotoxic chemotherapy - 2 weeks
Targeted anti-leukemic agents (FLT-3, IDH, menin inhibitors) - 3 half-lives of the medication
Radiotherapy - 1 week
donor lymphocyte infusions - 6 weeks
hematopoietic growth factors (filgrastim, TPO agonists, EPO) - 1 week
biologic therapy (monoclonal antibodies, T-cell engagers) - 2 weeks
Immune effector cellular therapy - 4 weeks
Intrathecal chemotherapy for treatment of active CNS leukemia - there must be at least two CSF samples negative for leukemia separated by one week before enrollment.
WBC shall be \< 25,000 before infusion. Hydroxyurea is permitted until day -3 to control excess blast proliferation. No other systemic treatment is allowed after the screening bone marrow is performed for inclusion in protocol
All prior treatment related toxicities should have resolved to ≤ grade 1 prior to study enrollment
agrees to use of adequate contraception from study enrollment to 4 months after cell infusion
voluntary written consent

Exclusion Criteria

Myeloid neoplasms with known or strongly suspected germline background, except DDX41, TP53, or RUNX1.
Acute promyelocytic leukemia (APL)
myocardial infarction (MI) within previous 6 months of study enrollment
pregnant or breastfeeding
Active CNS involvement with AML
new or progressive pulmonary infiltrates
active autoimmune disease requiring immunosuppressive therapy
Preexisting inflammatory disease requiring immunosuppressive therapy
history of severe asthma and currently on chronic systemic medications
HIV-1/2 positivity or hepatitis C/B
active systemic infections requiring anti-infective treatment
received any investigational agent within the 14 days before the start of study treatment (1st dose of fludarabine)
Patients with second malignancies are excluded if they have required systemic cytotoxic chemotherapy within 1 year or if they are not in remission
Exception: patients that are on stable dosing of hormonal therapy (e.g. aromatase inhibitor or antiandrogen therapy) for active breast or prostate cancer for 1 year are eligible.
Patients with excised basal cell or squamous cell carcinoma of the skin are eligible.
Patients with excised carcinoma in situ of the cervix or breast are eligible.
Patients with untreated T1a or T1b prostate cancer are eligible.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Minneapolis?

Yes, this clinical trial (NCT07591649) has an active research site in Minneapolis, MN that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Relapsed Adult AML Treatment Options in Minneapolis, MN

If you're searching for relapsed adult aml treatment options in Minneapolis, MN, this clinical trial (NCT07591649) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Minneapolis research site is actively enrolling participants for this clinical trial. You'll receive care from experienced relapsed adult aml specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all relapsed adult aml clinical trials near you to find additional studies recruiting in your area.

More Leukemia Trials in Minneapolis, MN

See all leukemia clinical trials recruiting in Minneapolis — not just this study.

Browse Leukemia Trials in Minneapolis →

Browse More Trials by Condition

Leukemia TrialsAcute Myeloid Leukemia TrialsAlzheimers Disease TrialsAntiphospholipid Syndrome TrialsAtopic Dermatitis TrialsErectile Dysfunction TrialsAll Conditions →

Ready to Join in Minneapolis?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Minneapolis, MN